Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the trial was halted early for futility, highlighting the complexity of AF-related neurocognitive impairment.
White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances

White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances

This review synthesizes recent large-scale multi-cohort studies revealing white matter microstructural abnormalities—especially free water increases—in limbic tracts as critical markers of cognitive decline in aging and Alzheimer's disease, emphasizing integrated biomarker approaches.
Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.